Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Pages: 283 Published: March 31, 2022 Report Code: GMDGDHC22025TDB

Tyrosine Protein Kinase JAK1 pipeline market research report provides comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

Key MoA in the Tyrosine Protein Kinase JAK1 Pipeline Market

The key MoA in the Tyrosine Protein Kinase JAK1 pipeline market is Tyrosine Protein Kinase JAK1 Inhibitor.

Key RoA in the Tyrosine Protein Kinase JAK1 Pipeline Market

The key RoA in the Tyrosine Protein Kinase JAK1 pipeline market are oral, topical, ophthalmic, cutaneous, inhalational, and intravitreal. Oral has the highest pipeline products.

Tyrosine Protein Kinase JAK1 Pipeline Market, by RoA

Tyrosine Protein Kinase JAK1 Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Tyrosine Protein Kinase JAK1 Pipeline Market

The key molecule types in the Tyrosine Protein Kinase JAK1 pipeline market is small molecule.

Key Companies in the Tyrosine Protein Kinase JAK1 Pipeline Market

The key companies in the Tyrosine Protein Kinase JAK1 pipeline market are AbbVie Inc, Aclaris Therapeutics Inc, Alexion Pharmaceuticals Inc, Aqilion AB, Ashvattha Therapeutics LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, and Celon Pharma SA. AbbVie Inc has the highest pipeline products.

Tyrosine Protein Kinase JAK1 Pipeline Market, by Companies

Tyrosine Protein Kinase JAK1 Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key MoA Tyrosine Protein Kinase JAK1 Inhibitor
Key RoA Oral, Topical, Ophthalmic, Cutaneous, Inhalational, and Intravitreal
Key molecule type Small Molecule
Key companies AbbVie Inc, Aclaris Therapeutics Inc, Alexion Pharmaceuticals Inc, Aqilion AB, Ashvattha Therapeutics LLC, Astellas Pharma Inc, Bristol-Myers Squibb Co, and Celon Pharma SA

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Players

  • AbbVie Inc

    Aclaris Therapeutics Inc

    Alexion Pharmaceuticals Inc

    Aqilion AB

    Ashvattha Therapeutics LLC

    Astellas Pharma Inc

    Bristol-Myers Squibb Co

    Celon Pharma SA

    Concert Pharmaceuticals Inc

    Dizal (Jiangsu) Pharmaceutical Co Ltd

    Eli Lilly and Co

    EQRx Inc

    Galapagos NV

    GlaxoSmithKline Plc

    Han Wha Pharma Co Ltd

    Hangzhou East China Pharmaceutical Group Co Ltd

    HK inno.N Corp

    Impetis Biosciences Ltd

    Incyte Corp

    Japan Tobacco Inc

    Jiangsu Carephar Pharmaceutical Co Ltd

    Jiangsu Hengrui Medicine Co Ltd

    Jiangsu Vcare PharmaTech Co Ltd

    Kinaset Therapeutics Inc

    Lynk Pharmaceutical Hangzhou Co Ltd

    Merck & Co Inc

    Nippon Shinyaku Co Ltd

    Pfizer Inc

    Sareum Holdings Plc

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

    Shenzhen Chipscreen Biosciences Co Ltd

    Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd

    Sierra Oncology Inc

    Simcere Pharmaceutical Group Ltd

    The United Laboratories International Holdings Ltd

    Theravance Biopharma Inc

    TLL Pharmaceutical LLC

    Wuxi Fuxin Pharmaceutical Research and Development Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Overview

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Companies Involved in Therapeutics Development

AbbVie Inc

Aclaris Therapeutics Inc

Alexion Pharmaceuticals Inc

Aqilion AB

Ashvattha Therapeutics LLC

Astellas Pharma Inc

Bristol-Myers Squibb Co

Celon Pharma SA

Concert Pharmaceuticals Inc

Dizal (Jiangsu) Pharmaceutical Co Ltd

Eli Lilly and Co

EQRx Inc

Galapagos NV

GlaxoSmithKline Plc

Han Wha Pharma Co Ltd

Hangzhou East China Pharmaceutical Group Co Ltd

HK inno.N Corp

Impetis Biosciences Ltd

Incyte Corp

Japan Tobacco Inc

Jiangsu Carephar Pharmaceutical Co Ltd

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Vcare PharmaTech Co Ltd

Kinaset Therapeutics Inc

Lynk Pharmaceutical Hangzhou Co Ltd

Merck & Co Inc

Nippon Shinyaku Co Ltd

Pfizer Inc

Sareum Holdings Plc

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shenzhen Chipscreen Biosciences Co Ltd

Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd

Sierra Oncology Inc

Simcere Pharmaceutical Group Ltd

The United Laboratories International Holdings Ltd

Theravance Biopharma Inc

TLL Pharmaceutical LLC

Wuxi Fuxin Pharmaceutical Research and Development Co Ltd

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Drug Profiles

(elsubrutinib + upadacitinib) – Drug Profile

Product Description

Mechanism Of Action

History of Events

A-223 – Drug Profile

Product Description

Mechanism Of Action

abrocitinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

AQ-280 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ARQ-255 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ATI-1777 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ATI-501 – Drug Profile

Product Description

Mechanism Of Action

History of Events

baricitinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

CDD-2603 – Drug Profile

Product Description

Mechanism Of Action

History of Events

cerdulatinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

CJ-15314 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CPL-409116 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CS-12192 – Drug Profile

Product Description

Mechanism Of Action

delgocitinib – Drug Profile

Product Description

Mechanism Of Action

History of Events

deuruxolitinib phosphate – Drug Profile

Product Description

Mechanism Of Action

History of Events

Drugs to Inhibit JAK1 for Autoimmune Disorders – Drug Profile

Product Description

Mechanism Of Action

DZD-4205 – Drug Profile

Product Description

Mechanism Of Action

History of Events

EQ-121 – Drug Profile

Product Description

Mechanism Of Action

History of Events

filgotinib maleate – Drug Profile

Product Description

Mechanism Of Action

History of Events

FZJ-003 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GLPG-0555 – Drug Profile

Product Description

Mechanism Of Action

History of Events

GLPG-3121 – Drug Profile

Product Description

Mechanism Of Action

History of Events

INCB-54707 – Drug Profile

Product Description

Mechanism Of Action

History of Events

itacitinib adipate – Drug Profile

Product Description

Mechanism Of Action

History of Events

ivarmacitinib sulfate – Drug Profile

Product Description

Mechanism Of Action

History of Events

KFPH-018 – Drug Profile

Product Description

Mechanism Of Action

LNK-01001 – Drug Profile

Product Description

Mechanism Of Action

History of Events

momelotinib dihydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

NS-229 – Drug Profile

Product Description

Mechanism Of Action

OB-756 – Drug Profile

Product Description

Mechanism Of Action

Opzelura – Drug Profile

Product Description

Mechanism Of Action

History of Events

peficitinib hydrobromide – Drug Profile

Product Description

Mechanism Of Action

History of Events

PNQ-401 – Drug Profile

Product Description

Mechanism Of Action

History of Events

PNQ-701 – Drug Profile

Product Description

Mechanism Of Action

History of Events

ruxolitinib phosphate – Drug Profile

Product Description

Mechanism Of Action

History of Events

SAR-20347 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SDC-1801 – Drug Profile

Product Description

Mechanism Of Action

History of Events

SDC-1802 – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1 and TYK2 for Rheumatoid Arthritis – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1 for Rheumatoid Arthritis – Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit JAK1 and JAK3 for Inflammation – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit JAK1, JAK2, JAK3 and TYK2 for Dermatology – Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Moleucle to Inhibit JAK 1 and JAK 2 for Inflammation – Drug Profile

Product Description

Mechanism Of Action

History of Events

TLL-018 – Drug Profile

Product Description

Mechanism Of Action

History of Events

upadacitinib ER – Drug Profile

Product Description

Mechanism Of Action

History of Events

VC-005 – Drug Profile

Product Description

Mechanism Of Action

History of Events

VR-588 – Drug Profile

Product Description

Mechanism Of Action

History of Events

WXFL-10203614 – Drug Profile

Product Description

Mechanism Of Action

WXSH-0150 – Drug Profile

Product Description

Mechanism Of Action

YJC-50018 – Drug Profile

Product Description

Mechanism Of Action

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Dormant Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Discontinued Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC

2.7.10.2) – Product Development Milestones

Featured News & Press Releases

Mar 07, 2022: Another lifesaving COVID-19 drug identified

Feb 28, 2022: Lynk Pharmaceuticals announces first patient dosed in phase II clinical study of LNK01001in patients with atopic dermatitis

Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn’s disease

Feb 24, 2022: Second phase 3 induction study confirms Upadacitinib (RINVOQ) improved clinical and endoscopic outcomes in patients with Crohn’s disease

Feb 18, 2022: Dizal Pharmaceutical receives U.S. FDA Fast Track Designation for DZD4205 (Golidocitinib) for the treatment of refractory or relapsed peripheral T-cell lymphoma

Feb 17, 2022: WHO recommends Baricitinib for Covid-19

Feb 02, 2022: Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress

Jan 28, 2022: Updates on OLUMIANT (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis

Jan 25, 2022: Sierra Oncology provides financial update to support the future commercialization of momelotinib

Jan 25, 2022: Sierra Oncology announces momelotinib achieved statistically significant benefit on symptoms, anemia and splenic size in the pivotal MOMENTUM study for myelofibrosis

Jan 20, 2022: Lynk doses first patient in Phase II ankylosing spondylitis drug trial

Jan 19, 2022: Momelotinib review article published in Journal of Hematology & Oncology highlights importance of anemia benefit for Myelofibrosis Patients

Jan 18, 2022: Sierra Oncology updates topline data timing for pivotal phase 3 trial of momelotinib in myelofibrosis

Jan 18, 2022: Jyseleca (filgotinib) licensed for the treatment of adult patients with moderately to severely active ulcerative colitis in Great Britain

Jan 17, 2022: MSF responds to latest WHO recommendation for COVID-19 medicine baricitinib

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Indications, 2022 (Contd..3)

Number of Products under Development by Indications, 2022 (Contd..4)

Number of Products under Development by Indications, 2022 (Contd..5)

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Products under Development by Companies, 2022 (Contd..7)

Products under Development by Companies, 2022 (Contd..8)

Products under Development by Companies, 2022 (Contd..9)

Products under Development by Companies, 2022 (Contd..10)

Products under Development by Companies, 2022 (Contd..11)

Products under Development by Companies, 2022 (Contd..12)

Products under Development by Companies, 2022 (Contd..13)

Products under Development by Companies, 2022 (Contd..14)

Products under Development by Companies, 2022 (Contd..15)

Products under Development by Companies, 2022 (Contd..16)

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by AbbVie Inc, 2022

Pipeline by Aclaris Therapeutics Inc, 2022

Pipeline by Alexion Pharmaceuticals Inc, 2022

Pipeline by Aqilion AB, 2022

Pipeline by Ashvattha Therapeutics LLC, 2022

Pipeline by Astellas Pharma Inc, 2022

Pipeline by Bristol-Myers Squibb Co, 2022

Pipeline by Celon Pharma SA, 2022

Pipeline by Concert Pharmaceuticals Inc, 2022

Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, 2022

Pipeline by Eli Lilly and Co, 2022

Pipeline by EQRx Inc, 2022

Pipeline by Galapagos NV, 2022

Pipeline by GlaxoSmithKline Plc, 2022

Pipeline by Han Wha Pharma Co Ltd, 2022

Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, 2022

Pipeline by HK inno.N Corp, 2022

Pipeline by Impetis Biosciences Ltd, 2022

Pipeline by Incyte Corp, 2022

Pipeline by Japan Tobacco Inc, 2022

Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022

Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022

Pipeline by Jiangsu Vcare PharmaTech Co Ltd, 2022

Pipeline by Kinaset Therapeutics Inc, 2022

Pipeline by Lynk Pharmaceutical Hangzhou Co Ltd, 2022

Pipeline by Merck & Co Inc, 2022

Pipeline by Nippon Shinyaku Co Ltd, 2022

Pipeline by Pfizer Inc, 2022

Pipeline by Sareum Holdings Plc, 2022

Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, 2022

Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022

Pipeline by Sichuan Kelun Bio-Tech Pharmaceutical Co Ltd, 2022

Pipeline by Sierra Oncology Inc, 2022

Pipeline by Simcere Pharmaceutical Group Ltd, 2022

Pipeline by The United Laboratories International Holdings Ltd, 2022

Pipeline by Theravance Biopharma Inc, 2022

Pipeline by TLL Pharmaceutical LLC, 2022

Pipeline by Wuxi Fuxin Pharmaceutical Research and Development Co Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Dormant Products, 2022 (Contd..2)

Dormant Products, 2022 (Contd..3)

Dormant Products, 2022 (Contd..4)

Discontinued Products, 2022

Discontinued Products, 2022 (Contd..1)

Discontinued Products, 2022 (Contd..2)

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Type, 2022

Frequently Asked Questions

$3500

Can be used by individual purchaser only

$10500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.